Laura Shawver sold $560k of SPRY
director at ARS Pharmaceuticals, Inc.. 50,000 shares at an average of $11.21, traded Mar 5, 2025, filed Mar 7, 2025.
Score components
- +15RoleDirector
- +19Trade size$560k at market
- +5Share of holdings soldSold 24% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-007438, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 5, 2025 | MOption exercise Common Stock10b5-1 | +400 | $4.85 | $1,940 | 210,746 | Mar 7, 2025 |
| Mar 5, 2025 | SOpen-market sale Common Stock10b5-1 | -400 | $11.00 | $4,400 | 210,346 | Mar 7, 2025 |
| Mar 6, 2025 | MOption exercise Common Stock10b5-1 | +49,600 | $4.85 | $241k | 259,946 | Mar 7, 2025 |
| Mar 6, 2025 | SOpen-market sale Common Stock10b5-1 | -49,600 | $11.21 | $556k | 210,346 | Mar 7, 2025 |
| Mar 5, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -400 | $0.00 | $0 | 123,664 | Mar 7, 2025 |
| Mar 6, 2025 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -49,600 | $0.00 | $0 | 74,064 | Mar 7, 2025 |
Related signals
Other insiders at ARS Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 45Moderate | ARS Pharmaceuticals, Inc. | Brian Dorsey Chief Operating Officer | $190k 21,828 shares | -67% | |
| 53Moderate | ARS Pharmaceuticals, Inc. | Justin Chakma Chief Business Officer | $1.5M 166,380 shares | -100% | |
| 34Weak | ARS Pharmaceuticals, Inc. | Kathleen D. Scott Chief Financial Officer | $188k 12,500 shares | -55% | |
| 41Moderate | ARS Pharmaceuticals, Inc. | Richard E Lowenthal PRESIDENT AND CEO | $724k 50,000 shares | -4% | |
| 31Weak | ARS Pharmaceuticals, Inc. | Sarina Tanimoto CHIEF MEDICAL OFFICER | $704k 50,000 shares | -4% | |
| 21Weak | ARS Pharmaceuticals, Inc. | Eric Karas Chief Commercial Officer | $255k 15,000 shares | -59% | |
| 50Moderate | ARS Pharmaceuticals, Inc. | James E Flynn owner | $14M 740,149 shares | -14% | |
| 21Weak | ARS Pharmaceuticals, Inc. | Eric Karas Chief Commercial Officer | $240k 15,000 shares | -66% | |
| 63Notable | ARS Pharmaceuticals, Inc. | Kathleen D. Scott Chief Financial Officer | $705k 50,000 shares | -87% | |
| 60Notable | ARS Pharmaceuticals, Inc. | Brent L Saunders director | $1.7M 120,000 shares | -100% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.